Moberg Pharma Ab · OMXSTO:MOB
Moberg Pharma Ab — Investor Presentation (August 2026)
19 slides from Moberg Pharma Ab's investor presentation, Aug 13, 2026
Slide 1: A novel topical treatment for onychomycosis – introducing Terclara
A novel topical treatment for onychomycosis – introducing Terclara® August 2026
Slide 2: Disclaimer
Disclaimer The purpose of this presentation (the "Presentation") is to provide an overview of Moberg Pharma AB (publ) (the "Company"). For the purposes of this notice, "Presentation" means this document, its contents or any part of it, any oral presentation, any question or answer session and any wr
Slide 3: Potential new global market leader in Onychomycosis
Potential new global market leader in Onychomycosis Terclara® is a new Market approvals Very successful launch in topical treatment for nail in place in 14 countries Scandinavia, European fungus based on rollout ongoing terbinafine
Slide 4: Oral terbinafine is the gold standard for treatment of toenail fungus
Oral terbinafine is the gold standard for treatment of toenail fungus x40 Terclara® delivers terbinafine terbinafine in nailbed directly and effectively to the nail with Terclara® vs levels seen with oral treatment* x1,000 76% less terbinafine with Terclara® (MOB-015) in mycological cure* plasma vs
Slide 5: Terclara differentiating features
Terclara® differentiating features • Terbinafine, a well-known antifungal agent with: • Negligible systemic absorption but concentration of • fungicidal effect unlike many other antifungal drugs terbinafine 1000x in the nail and 40x in the nail bed when • widespread use both under the oral Rx or top
Slide 6: Overview of Phase 3 studies that supported EU approval
Overview of Phase 3 studies that supported EU approval Europe North America Number of patients 452 365 Comparator 8% ciclopirox Vehicle Complete cure @52w Non inferiority met Superiority met Mycological cure rate @52w 84% 70% Improvement of nail condition 70% 82% @12w (patient subjective score) • Pr
Slide 7: Strong commercial partners in place
Strong commercial partners in place • Partners in place for Europe, Canada, APAC, China, Scandinavia, Israel • Latest addition: Karo Healthcare, a capable partner with global reach – Lamisil®: The leading global brand for onychomycosis – Established distribution across all major pharmacies – Proven
Slide 8: Terclara is approved in 13 European countries
Terclara® is approved in 13 European countries Market approvals • Austria - OTC • France - Rx • Norway - • Belgium - OTC • Hungary - OTC OTC • Czech Rep. - Rx • Ireland - Rx • Spain - Rx • Denmark - Rx • Italy - OTC • Sweden - OTC • Finland - Rx • Netherlands - OTC Pipeline of additional approvals f
Slide 9: Why does Terclara win with patients?
Why does Terclara® win with patients? ▸ Kills the fungus ▸ It is safe ▸ Easy to apply ▸ Quick visible improvement * Mantap marketing survey, 2023
Slide 10: Strong premium position from true advantage
Strong premium position from true advantage Terclara´s mycological cure rate OTC Terabinafin allows for a price premium Mycological cure 76% Mycological cure OTC Amorolfin Mycological cure approx. 20%* Products based on devices Unclear to low cure Cosmetic Medical
Slide 11: 70+ million patients in Europe need better treatment for nail fungus
70+ million patients in Europe need better treatment for nail fungus 10% of the population 7/10 doctors avoid prescribing suffer from nail terbinafine tablets2 fungus1 USD 2bn global onychomycosis market.3 1) PLoS Pathog. 2014 Jun; 10(6): e1004105. 2) due to patients´ concerns for serious side effec
Slide 12: Strong drivers behind underlying market growth
Strong drivers behind underlying market growth 1. High prevalence 2. Aging population 3. Lifestyle factors 4. Growing aesthetic concerns 5. Rising awareness and willingness to treat * Grand View Research, Mordorin Intelligence, GMI, Research & Markets
Slide 13: Terclara expands the market
Terclara® expands the market Terclara’s strong proposition for consumers 100% prevalence unlocks the market growth = 100% usage potential Conversion of non- treaters 44% do not Growth potential treat Conversion Market of “mal- potential treaters” Users of Increased deferior frequency products Satisf
Slide 14: Terclara continues to improve its market leading position in Sweden
Terclara® continues to improve its market leading position in Sweden 44% 37% Terclara® has become the Terclara® value share Terclara® volume share clear market leader and no. of units driven category growth – in a highly competitive market * IQVIA MIDAS, Pharmacy Sell-Out data, rolling 12 months, Ju
Slide 15: Awarded 'Launch of the year' 2024 by major Swedish pharmacies
Awarded ’Launch of the year’ 2024 by major Swedish pharmacies DOZ pharmacy chain: 'A world class launch that has revitalized the category. The product has quickly become a market leader, driving progress forward and helping us gain market share. With the support of educational materials, we have tog
Slide 16: Terclara maintains its market leading position in Norway
Terclara® maintains its market leading position in Norway as second launch year progresses Terclara® launch 36% Terclara® 32% Terclara® value share volume share nominated for “Launch no. of units of the Year 2025” by the pharmacy chains Apotek 1 and Alliance Healthcare * IQVIA MIDAS, Pharmacy Sell-I
Slide 17: Moberg Pharma, a pharma company with a strong track record
Behind Terclara: Moberg Pharma, a pharma company with a strong track record • Moberg Pharma’s R&D is based on discoveries of late Dr. Sven Moberg of Sahlgrenska University Hospital in Gothenburg, Sweden. • All Moberg Pharma products contains a patented keratolytic carrier which also promotes the vis
Slide 18: Executive summary
Executive summary ► Unprecedented ability to ► Terclara® became the market kill dermatophytes: 76% of patients leader in Sweden and Norway became fungus free, in two phase 3- instantly after starting consumer studies (800+ patients) marketing ► Terbinafine, the gold standard active for ► Partners in
Slide 19: Thank you!
PHARMA Thank you!